Amyloid-β and tau biomarkers can differentiate clinical phenotype in dementia with Lewy Bodies


  • In people with probable dementia with Lewy Bodies, positivity of amyloid-ß biomarkers is more common in APOE e4 carriers, particularly at advanced age.

Why this matters

    This study is the first to report the frequency of amyloid-β and tau biomarkers and several influencing factors in probable dementia with Lewy Bodies across a wide age range.  These findings could facilitate diagnosis, prognosis, and disease monitoring in clinical practice, and also provide valuable information for clinical trials targeting disease-specific proteins in dementia with Lewy Bodies.